Compare BMEA & PZG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | PZG |
|---|---|---|
| Founded | 2017 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 140.0M |
| IPO Year | 2021 | 2015 |
| Metric | BMEA | PZG |
|---|---|---|
| Price | $1.57 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.83 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 591.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $330,259.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.43 |
| 52 Week High | $3.07 | $2.70 |
| Indicator | BMEA | PZG |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 47.21 |
| Support Level | $1.17 | $1.50 |
| Resistance Level | $1.66 | $1.88 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 42.24 | 59.30 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.